Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Conditions

Sarcoma 4Glioma 4Thyroid Neoplasms 3Colorectal Neoplasms 3Central Nervous System Neoplasms 3Wilms Tumor 2Solid Tumors Harboring NTRK Fusion 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasms 2Multiple Myeloma 2Melanoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Lung Neoplasms 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Ependymoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Xanthogranuloma, Juvenile 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Tumors Harboring NTRK Fusion 1Stomach Neoplasms 1

Interventions

larotrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Tumors Harboring NTRK Fusion × larotrectinib × Clear all
NCT03025360 2019-12-19

Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion

Bayer

Approved for marketing

Tumors Harboring NTRK Fusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡